Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDXI research report →
Price Chart
About the company
Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity.
- CEO
- David G. Watumull
- IPO
- 2013
- Employees
- 10
- HQ
- Honolulu, HI, US
Get TickerSpark's AI analysis on CDXI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $80
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -1.81
- Div Yield
- 0.00%
- Gross Margin
- 63.61%
- Op Margin
- -568.26%
- Net Margin
- -938.04%
- ROE
- 58.12%
- ROIC
- 57.33%
Latest fiscal year · YoY change
- Revenue
- $538.95K-24.2%
- Gross Profit
- $342.82K-6.2%
- Op Income
- $-3,062,636
- Net Income
- $-5,055,507+0.7%
- EPS
- $-6.79+19.2%
- OCF Growth
- +49.1%
- FCF Growth
- +49.6%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -3.20
- RSI (14)
- 52
- Avg Volume
- 1
No earnings-call transcripts are available for CDXI yet.
- Free Float
- 73.5%
- Shares Outstanding
- 802.52K
- Float Shares
- 590.20K
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 14 | PAULSON CAPITAL (DELAWARE) CORP. | buy | 500,000 |
| Feb 24, 14 | Paulson Cardax Investments 1 LLC | buy | 500,000 |
| Feb 7, 14 | Paulson Cardax Investments 1 LLC | other | 1,068,477 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 1,068,477 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 0 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 0 |
| Feb 7, 14 | PAULSON CAPITAL (DELAWARE) CORP. | other | 3,872,434 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CDXI coverage
Recent articles, reports, and earnings notes.
No research on CDXI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CDXI report →